{"altmetric_id":4683841,"selected_quotes":["MCUR NEWS This study has been completed. processed this record on June 19, 2016","@roiev123 That's my concern, although the trial in question is double-blinded","$MCUR Phase 3 trial w\/est Jun completion date NCT01421966: Trial Tracker","$ICLR Phase 3 trial w\/est Jun completion date NCT01421966: Trial Tracker"],"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Macrocure Ltd."],"first_seen_on":"2015-10-28T11:19:47+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1466510583,"links":["https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01421966","https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01421966","http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01421966"],"nct_id":"NCT01421966","pubdate":"2011-08-21T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Evaluation of CureXcell\u00ae in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes","type":"clinical_trial_study_record"},"altmetric_score":{"score":32.5,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":32.5},"context_for_score":{"all":{"total_number_of_other_articles":7926939,"mean":6.7044594278339,"rank":250246,"this_scored_higher_than_pct":96,"this_scored_higher_than":7676362,"rank_type":"exact","sample_size":7926939,"percentile":96},"similar_age_3m":{"total_number_of_other_articles":241953,"mean":9.6453827701361,"rank":13134,"this_scored_higher_than_pct":94,"this_scored_higher_than":228800,"rank_type":"exact","sample_size":241953,"percentile":94},"this_journal":{"total_number_of_other_articles":21809,"mean":10.40054282832,"rank":825,"this_scored_higher_than_pct":96,"this_scored_higher_than":20981,"rank_type":"exact","sample_size":21809,"percentile":96},"similar_age_this_journal_3m":{"total_number_of_other_articles":1050,"mean":14.545714013346,"rank":64,"this_scored_higher_than_pct":93,"this_scored_higher_than":985,"rank_type":"exact","sample_size":1050,"percentile":93}}},"demographics":{"poster_types":{"member_of_the_public":3},"users":{"twitter":{"cohorts":{"Members of the public":3}}},"geo":{"twitter":{"US":2}}},"counts":{"total":{"posts_count":8},"news":{"unique_users_count":4,"unique_users":["biospace","bioportfolio","medcity_news","reuters"],"posts_count":4},"twitter":{"unique_users_count":3,"unique_users":["fda_tracker","DewDiligence","balamidas"],"posts_count":4}},"posts":{"news":[{"title":"Macrocure Stock Plunges 63% as Lead Drug Fails Phase III Study","url":"http:\/\/ct.moreover.com\/?a=23179901557&p=1pl&v=1&x=WIXgk9b9H20agsIX73UCFw","license":"public","citation_ids":[4683841],"posted_on":"2015-10-28T00:00:00+00:00","summary":"Macrocure Ltd. Announces Results for Phase III Clinical Trial of CureXcell(R) in Diabetic Foot Ulcers and Provides Corporate Update PETACH TIKVA, Israel, Oct.","author":{"name":"Biospace","url":"http:\/\/www.biospace.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/375\/normal\/biospace.png?1437140433"}},{"title":"Macrocure Ltd. Announces Results for Phase III Clinical Trial of CureXcell(R) in Diabetic Foot Ulcers and Provides Corporate Update","url":"http:\/\/ct.moreover.com\/?a=23171965484&p=1pl&v=1&x=4gYDZZWmT6FyXr5BwsWNtA","license":"public","citation_ids":[4683841],"posted_on":"2015-10-27T00:00:00+00:00","summary":"PETACH TIKVA, Israel, Oct. 27, 2015 (GLOBE NEWSWIRE) -- Macrocure Ltd. (\"Macrocure\" or the \"Company\") (NASDAQ:MCUR), a clinical-stage biotechnology company focused on advancing its novel therapeutic platform to address chronic and hard-to-heal wounds\u2026","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}},{"title":"Israeli white blood cell-based wound care serum headed stateside","url":"http:\/\/medcitynews.com\/2014\/11\/israeli-white-blood-cell-based-wound-care-serum-headed-stateside\/","license":"public","citation_ids":[4683841,4685879],"posted_on":"2014-11-12T11:30:02+00:00","summary":"In war, and in wound care, sometimes success is as simple as sending in reinforcements to the site of conflict. Israeli biopharma Macrocure has developed a serum filled with hyperactivated immune cells \u2013...","author":{"name":"Medcity News","url":"http:\/\/medcitynews.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/957\/normal\/Screen_Shot_2016-02-02_at_16.37.55.png?1454431086"}},{"title":"Macrocure Ltd. Announces Results for Phase III Clinical Trial of CureXcell(R) in Diabetic Foot Ulcers and Provides Corporate Update","url":"http:\/\/ct.moreover.com\/?a=23171887549&p=1pl&v=1&x=3qwpd8MdoGIX7Pv71pyUPA","license":"public","citation_ids":[4683841],"posted_on":"2015-10-27T21:30:48+00:00","summary":"PETACH TIKVA, Israel, Oct. 27, 2015 (GLOBE NEWSWIRE) -- Macrocure Ltd. (\"Macrocure\" or the \"Company\") (NASDAQ:MCUR), a clinical-stage biotechnology company focused on advancing its novel therapeutic platform to address chronic and hard-to-heal wounds\u2026","author":{"name":"Reuters","url":"http:\/\/www.reuters.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/008\/normal\/reuters.png?1369846897"}}],"twitter":[{"url":"https:\/\/twitter.com\/fda_tracker\/status\/611172653131390976","license":"datasift","citation_ids":[4683841],"posted_on":"2015-06-17T14:04:50+00:00","author":{"name":"FDA Tracker","url":"http:\/\/www.fdatracker.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1667207308\/square_logo_normal.png","description":"Analytics for Pharma and Biotech Traders","id_on_source":"fda_tracker","tweeter_id":"391492257","geo":{"lt":37.77493,"ln":-122.41942,"country":"US"},"followers":2946},"tweet_id":"611172653131390976"},{"url":"https:\/\/twitter.com\/fda_tracker\/status\/615883738258341888","license":"datasift","citation_ids":[4683841],"posted_on":"2015-06-30T14:05:00+00:00","author":{"name":"FDA Tracker","url":"http:\/\/www.fdatracker.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1667207308\/square_logo_normal.png","description":"Analytics for Pharma and Biotech Traders","id_on_source":"fda_tracker","tweeter_id":"391492257","geo":{"lt":37.77493,"ln":-122.41942,"country":"US"},"followers":2946},"tweet_id":"615883738258341888"},{"url":"https:\/\/twitter.com\/DewDiligence\/status\/619554407747821568","license":"datasift","citation_ids":[4683841],"posted_on":"2015-07-10T17:10:56+00:00","author":{"name":"Roy Friedman","url":"http:\/\/investorshub.advfn.com\/boards\/board.aspx?board_id=1418","image":"https:\/\/pbs.twimg.com\/profile_images\/1705041972\/bar-goose_ihub_normal.png","description":"Professional portfolio manager and director of private foundation; former tournament backgammon player \/ author.","id_on_source":"DewDiligence","tweeter_id":"442298073","geo":{"lt":42.36565,"ln":-71.10832,"country":"US"},"followers":5144},"tweet_id":"619554407747821568"},{"url":"http:\/\/twitter.com\/balamidas\/statuses\/745225516869771264","license":"gnip","citation_ids":[4683841],"posted_on":"2016-06-21T12:03:03+00:00","author":{"name":"Nick","image":"https:\/\/abs.twimg.com\/sticky\/default_profile_images\/default_profile_6_normal.png","id_on_source":"balamidas","tweeter_id":"22060037","geo":{"lt":null,"ln":null},"followers":66},"tweet_id":"745225516869771264"}]}}